U.S. markets open in 5 hours 52 minutes

Ocuphire Pharma, Inc. (OCUP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.5400-0.1800 (-6.62%)
At close: 04:00PM EDT
2.5400 0.00 (0.00%)
After hours: 07:38PM EDT

Ocuphire Pharma, Inc.

37000 Grand River Avenue
Suite 120
Farmington Hills, MI 48335
United States
248 681 9815

Full Time Employees8

Key Executives

NameTitlePayExercisedYear Born
Ms. Mina Patel Sooch M.B.A., MBAFounder, CEO, Pres, Treasurer & Vice Chair of the Board801.03kN/A1968
Ms. Amy Zaremba Rabourn C.P.A., CPA, MAccVP of Fin. & Principal Accounting Officer332.09kN/A1981
Mr. Bernhard Hoffmann M.B.A.VP of Corp. Devel. & Operations and Sec.325.09kN/A1956
Dr. Daniela C. Oniciu Ph.D.Global Head of R&D, Chemistry and Product Devel.N/AN/AN/A
Dr. Mitchell Brigell Ph.D.Head of Clinical Devel. & StrategyN/AN/AN/A
Mr. Chris ErnstGlobal Head of QA & ManufacturingN/AN/AN/A
Ms. Bindu ManneHead of Market Devel. & CommercializationN/AN/AN/A
Mr. Erik SimsDirector & Corp. ControllerN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induced mydriasis, as well as that has completed Phase 2 VEGA-1 trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.

Corporate Governance

Ocuphire Pharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.